Genetic Testing Company Agrees to Pay $1.99 Million

February 14, 2019

GenomeDx Biosciences Corp. has agreed to pay $1.99 million to resolve allegations that it violated the False Claims Act by submitting false claims to Medicare for a post-operative genetic test for prostate cancer patients. The United States alleged that the company submitted claims to Medicare between September 2015 and June 2017 for the test that were not medically reasonable and necessary because the prostate cancer patients did not have risk factors necessitating the test. Read a Department of Justice press release.
FindFind Help in Your State